Freeport-McMoRan, AppLovin And A Major Healthcare Stock On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said AppLovin Corporation APP is the number one performing large cap stock of the year so far.

On April 16, Morgan Stanley analyst Matthew Cost maintained AppLovin with an Equal-Weight rating and raised the price target from $55 to $70.

Stephanie Link of Hightower said she likes Freeport-McMoRan Inc. FCX amid recovery in China.

On April 9, BofA Securities analyst Lawson Winder upgraded Freeport-McMoRan from Neutral to Buy and announced a $59 price target, while Scotiabank analyst Orest Wowkodaw maintained the stock with a Sector Outperform and raised the price target from $48 to $55.

Freeport-McMoRan is a top holding in the broader SPDR S&P Metals & Mining ETF XME.

Don’t forget to check out our premarket coverage here

Jim Lebenthal of Cerity Partners named CVS Health Corporation CVS, which is set to report quarterly earnings soon.

CVS Health is scheduled to hold a conference call with analysts and investors on May 1 to discuss first quarter 2024 financial results. Analysts expect the company to report quarterly earnings at $1.71 per share, down from $2.2 per share in the year-ago period. The company is projected to post quarterly revenue of $89.21 billion, up from $80.81 billion in the year-earlier quarter.

Price Action:

• AppLovin shares rose 1.3% to close at $72.32 on Tuesday.
• Freeport-McMoRan shares fell 1.2% to settle at $49.41 on Tuesday.
• CVS Health shares rose 0.1% to close at $69.03 during Tuesday’s session.

Check This Out: Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday